Literature DB >> 19007570

[Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery].

Montserrat Vendrell1, Javier de Gracia, Casilda Olveira, Miguel Angel Martinez-Garcia, Rosa Girón, Luis Máiz, Rafael Cantón, Ramon Coll, Amparo Escribano, Amparo Solé.   

Abstract

Bronchiectasis is the end result of several different diseases that share principles of management. The clinical course usually involves chronic bronchial infection and inflammation, which are associated with progression. The cause of bronchiectasis should always be investigated, particularly when it can be treated. We recommend evaluating etiology, symptoms, bronchial colonization and infection, respiratory function, inflammation, structural damage, nutritional status, and quality of life in order to assess severity and to monitor clinical course. Care should be supervised by specialized units, at least in cases of chronic bronchial infection, recurrent exacerbations, or when there is a cause that is likely to respond to treatment. Improving symptoms and halting progression are the goals of management, which is based on treatment of the underlying cause and of acute or chronic infections and on the drainage of secretions. Complications that arise must also be treated. Antibiotic prescription is guided by how well infection is being controlled, and this is indicated by the color of sputum and a reduction in the number of exacerbations. We recommend inhaled antibiotics in cases of chronic bronchial infection that does not respond to oral antibiotics, when these cause side effects, or when the cause is Pseudomonas species or other bacteria resistant to oral antibiotics. Inhaled administration is also advisable to treat initial colonization by Pseudomonas species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007570     DOI: 10.1157/13128330

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  43 in total

1.  Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin.

Authors:  Casilda Olveira; Alicia Padilla; Antonio Dorado; Victoria Contreras; Eduardo Garcia-Fuentes; Elehazara Rubio-Martin; Nuria Porras; Esperanza Doña; Ana Carmona; Gabriel Olveira
Journal:  Eurasian J Med       Date:  2017-06

2.  Surgical treatment of bronchiectasis: a retrospective observational study of 138 patients.

Authors:  Reda E Al-Refaie; Sameh Amer; Mohamed El-Shabrawy
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Authors:  Gerard Muñoz; Maria Buxó; Javier de Gracia; Casilda Olveira; Miguel Angel Martinez-Garcia; Rosa Giron; Eva Polverino; Antonio Alvarez; Surinder S Birring; Montserrat Vendrell
Journal:  Chron Respir Dis       Date:  2016-02-22       Impact factor: 2.444

Review 4.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Riesco; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; José Luis López-Campos; Joan B Soriano; Julio Ancochea
Journal:  Aten Primaria       Date:  2012-06-15       Impact factor: 1.137

Review 6.  Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.

Authors:  Joaquim Gea; Antoni Sancho-Muñoz; Roberto Chalela
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life.

Authors:  Casilda Olveira; Gabriel Olveira; Inmaculada Gaspar; Antonio Dorado; Ivette Cruz; Federico Soriguer; Alexandra L Quittner; Francisco Espildora
Journal:  Qual Life Res       Date:  2012-04-29       Impact factor: 4.147

8.  Validation of a Quality of Life Questionnaire for Bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0.

Authors:  Casilda Olveira; Gabriel Olveira; Francisco Espildora; Rosa-Maria Giron; Gerard Muñoz; Alexandra L Quittner; Miguel-Angel Martinez-Garcia
Journal:  Qual Life Res       Date:  2013-10-19       Impact factor: 4.147

9.  Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.

Authors:  David de la Rosa; Miguel-Angel Martínez-Garcia; Casilda Olveira; Rosa Girón; Luis Máiz; Concepción Prados
Journal:  Chron Respir Dis       Date:  2016-07-07       Impact factor: 2.444

10.  Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.

Authors:  R Somayaji; C H Goss
Journal:  Curr Pulmonol Rep       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.